Replies to post #8645 on Momenta Pharmaceuticals, Inc. (MNTA)

[linhdtu]

And with Uncle Ben keeping the interest rate to the floor for the next 2 yrs ( until 2014, end of 2013 I believe) the cost of financing such an M&A wouldn't be too onerous :)

[DewDiligence]

It would take the legal exposure off the table relating to MNTA and have a viable biosimilar program with a partner in place.

Two points that argue against such a scenario:

1. WPI’s acquiring MNTA would not necessarily remove WPI’s legal liability for the Lovenox launch. Insofar as there are two plaintiffs and two defendants in this litigation, it’s hard to say how such a transaction would affect the ultimate damage awards in the case.

2. WPI already has an FoB collaboration with AMGN (#msg-70097496).

Regards, Dew

[rwwine]

I for one think an offer of $22/share is grossly below what would be expected as a serious offer. Considering mCopax itself let alone the other irons in the fire, I would suggest perhaps an offer of $35-$40/share as more appropriate. Just my 2 cents. ;-)